within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX25_BaloxavirMarboxil;

model BaloxavirMarboxil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 2.8888888888888894e-06,
    adminDuration = 600,
    adminMass = 40 / 1000000,
    adminCount = 1,
    Vd = 0.0487,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008666666666666666,
    Tlag = 30.0,
    Vdp = 0.311,
    k12 = 2.091666666666667e-06,
    k21 = 2.091666666666667e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>BaloxavirMarboxil</td></tr><tr><td>ATC code:</td><td>J05AX25</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>40</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>48.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>10.4</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Baloxavir marboxil is an antiviral prodrug used in the treatment of influenza A and B. It inhibits the cap-dependent endonuclease activity of the viral polymerase, blocking viral replication. Approved and currently used for the treatment of acute, uncomplicated influenza in otherwise healthy adults and adolescents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose.</p><h4>References</h4><ol><li><p>Liu, Y, et al., &amp; De Buck, S (2022). Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals. <i>Clinical and translational science</i> 15(5) 1196–1203. DOI:<a href=\"https://doi.org/10.1111/cts.13237\">10.1111/cts.13237</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35176206/\">https://pubmed.ncbi.nlm.nih.gov/35176206</a></p></li><li><p>Kim, Y, et al., &amp; Lee, S (2022). Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects. <i>Clinical and translational science</i> 15(2) 422–432. DOI:<a href=\"https://doi.org/10.1111/cts.13160\">10.1111/cts.13160</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34664769/\">https://pubmed.ncbi.nlm.nih.gov/34664769</a></p></li><li><p>Retout, S, et al., &amp; Cosson, V (2022). A Pharmacokinetics-Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B. <i>Clinical pharmacology and therapeutics</i> 112(2) 372–381. DOI:<a href=\"https://doi.org/10.1002/cpt.2648\">10.1002/cpt.2648</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35585696/\">https://pubmed.ncbi.nlm.nih.gov/35585696</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AX25 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end BaloxavirMarboxil;
